Informations sur le produit
- IMes
- 1,3-Bis(2,4,6-Trimethylphenyl)Imidazole
- 1,3-Bis(2,4,6-trimethylphenyl)-1,3-dihydro-2H-imidazol-2-ylidene
- 1,3-Bis(2,4,6-trimethylphenyl)imidazole-2-ylidene
- 1,3-Bis(2,4,6-trimethylphenyl)imidazolin-2-ylidene
- 1,3-Bis(mesityl)imidazol-2-ylidene
- 1,3-Di(2,4,6-trimethylphenyl)imidazol-2-ylidene
- 1,3-Di-tert-mesitylimidazol-2-ylidene
- 1,3-Dihydro-1,3-bis(2,4,6-trimethylphenyl)-2H-imidazol-2-ylidene
- 1,3-Dihydro-1,3-bis(mesityl)-2H-imidazol-2-ylidene
- Voir d'autres synonymes
- 1,3-Dihydro-1,3-dimesityl-2H-imidazol-2-ylidene
- 1,3-Dimesityl-2-imidazolylidene
- 1,3-Dimesityl-4-imidazolin-2-ylidene
- 1,3-Dimesitylimidazolin-2-ylidene
- 2H-Imidazol-2-ylidene, 1,3-dihydro-1,3-bis(2,4,6-trimethylphenyl)-
- N,N′-Bis(2,4,6-trimethylphenyl)imidazolin-2-ylidene
1,3-Dimesitylimidazol-2-ylidene is a structural analog of epidermal growth factor (EGF) that has been shown to be effective in the treatment of diabetic patients. It has also been shown to inhibit the activity of aminotransferases and cation channels. This compound is synthesized by a palladium-catalyzed coupling reaction between 1,3-dimesitylimidazolium chloride and ethyl acrylate.